+

PE20080319A1 - Dihidrotienopirimidinas como agentes inhibidores de pde-4 - Google Patents

Dihidrotienopirimidinas como agentes inhibidores de pde-4

Info

Publication number
PE20080319A1
PE20080319A1 PE2007000470A PE2007000470A PE20080319A1 PE 20080319 A1 PE20080319 A1 PE 20080319A1 PE 2007000470 A PE2007000470 A PE 2007000470A PE 2007000470 A PE2007000470 A PE 2007000470A PE 20080319 A1 PE20080319 A1 PE 20080319A1
Authority
PE
Peru
Prior art keywords
5lambda4
pyrimidin
dihydro
phenyl
oxo
Prior art date
Application number
PE2007000470A
Other languages
English (en)
Inventor
Pascale Pouzet
Christoph Hoenke
Rolf Goeggel
Birgit Jung
Peter Nickolaus
Thomas Fox
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20080319A1 publication Critical patent/PE20080319A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE TIENOPIRIMIDINA DE FORMULA 1, DONDE X ES SO O SO2; R1 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ARILO C6-C10, ENTRE OTROS; R2 ES H, ALQUILO C1-C10, ALQUENILO C2-C6, ENTRE OTROS; R3 ES OH, Cl, NITRILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: {2-[4-(4-CLORO-FENIL)-PIPERAZINI-1-IL]-5-OXO-6,7-DIHIDRO-5H,5LAMBDA4-TIENO[3,2-d]PIRIMIDIN-4-IL}-(3-MORFOLIN-4-ILMETIL-FENIL)-AMINA, TRIFLUOROACETATO DE (R)-N2-{2-[4-(4-CLORO-FENIL)-PIPERAZIN-1-IL]-5-OXO-6,7-DIHIDRO-5H,5LAMBDA4-TIENO[3,2-d]PIRIMIDIN-4-IL)-3-METIL-BUTAN-1,2-DIAMINA, 4-{4-[4-(3-FLUORO-FENILAMINO)-5-OXO-6,7-DIHIDRO-5H,5LAMBDA4-TIENO[3,2-d]PIRIMIDIN-2-IL]-PIPERAZIN-1-IL}-N,N-DIMETILBENCENSULFONAMIDA, ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE PDE-4 Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS GASTROINTESTINALES O DE LAS VIAS RESPIRATORIAS, ENFERMEDADES INFLAMATORIAS DE LAS ARTICULACIONES, PIEL, OJOS, ENTRE OTRAS
PE2007000470A 2006-04-19 2007-04-17 Dihidrotienopirimidinas como agentes inhibidores de pde-4 PE20080319A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06112779A EP1847543A1 (de) 2006-04-19 2006-04-19 Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen

Publications (1)

Publication Number Publication Date
PE20080319A1 true PE20080319A1 (es) 2008-05-13

Family

ID=36847643

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000470A PE20080319A1 (es) 2006-04-19 2007-04-17 Dihidrotienopirimidinas como agentes inhibidores de pde-4

Country Status (20)

Country Link
US (3) US8114878B2 (es)
EP (2) EP1847543A1 (es)
JP (1) JP5214588B2 (es)
KR (1) KR20090009885A (es)
CN (1) CN101426505A (es)
AR (1) AR060516A1 (es)
AU (1) AU2007239573A1 (es)
BR (1) BRPI0710459A2 (es)
CA (1) CA2647243A1 (es)
CO (1) CO6140032A2 (es)
EA (1) EA200802051A1 (es)
EC (1) ECSP088738A (es)
IL (1) IL194739A0 (es)
MX (1) MX2008012915A (es)
NO (1) NO20083710L (es)
PE (1) PE20080319A1 (es)
TW (1) TW200808811A (es)
UY (1) UY30287A1 (es)
WO (1) WO2007118793A1 (es)
ZA (1) ZA200807015B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
MX2010003826A (es) * 2007-10-18 2010-04-21 Boehringer Ingelheim Int Preparacion de dihidrotieno [3,2-d] pirimidinas e intermedios usados en la misma.
WO2009050242A2 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
MX2010004026A (es) 2007-10-19 2010-04-30 Boehringer Ingelheim Int Piperidino-dihidrotienopirimidinas sustituidas.
WO2009053268A1 (de) * 2007-10-19 2009-04-30 Boehringer Ingelheim International Gmbh Neue phenyl-substituierte piperazino-dihydrothienopyrimidine
WO2009050236A1 (de) * 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Neue piperazino-dihydrothienopyrimidin-derivate
JP2012519159A (ja) * 2009-02-27 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pde4阻害剤及びnsaidを含有する複合薬
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
CN105037369B (zh) * 2015-06-23 2017-07-07 河南师范大学 一种吡唑并[5,1‑a]异吲哚‑3‑甲酰胺类化合物的合成方法
EP3675861A4 (en) * 2017-09-01 2021-01-06 Kadmon Corporation, LLC ALPHA SUPERWINDING PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
CN111108109A (zh) 2017-09-20 2020-05-05 利奥制药有限公司 取代的二氢噻吩并嘧啶及其作为磷酸二酯酶抑制剂的用途
WO2019081235A1 (en) 2017-10-23 2019-05-02 Boehringer Ingelheim International Gmbh NEW ASSOCIATION OF ACTIVE AGENTS FOR THE TREATMENT OF PROGRESSIVE FIBROSANT INTERSTITIAL PNEUMOPATHY (PF-ILD)
DK3724196T3 (da) 2017-12-15 2023-01-16 Union Therapeutics As Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere
WO2019115774A1 (en) 2017-12-15 2019-06-20 Leo Pharma A/S Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
EP3724195B1 (en) 2017-12-15 2023-12-27 UNION therapeutics A/S Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
IL312740A (en) 2021-12-09 2024-07-01 Boehringer Ingelheim Int A new oral pharmaceutical preparation and dosage regimen for the treatment of advanced interstitial and lymphoid lung diseases
MX2024006271A (es) 2021-12-09 2024-06-11 Boehringer Ingelheim Int Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
AU2023320795A1 (en) * 2022-08-09 2025-02-27 Xizang Haisco Pharmaceutical Co., Ltd. Pde4b inhibitor and use thereof
CN119947728A (zh) 2022-09-28 2025-05-06 勃林格殷格翰国际有限公司 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途
WO2024067660A1 (zh) 2022-09-29 2024-04-04 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物、其制备方法及其在医药上的应用
WO2025092985A1 (zh) * 2023-11-03 2025-05-08 合肥医工医药股份有限公司 磷酸二酯酶4b抑制剂及其制备方法与用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL124131C (es) 1963-06-17
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
NL123139C (es) 1965-03-31
BE754606A (fr) 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
DE1940572A1 (de) 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2032687A1 (en) 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (es) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
DE2121950A1 (en) 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de) 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
JPH07330777A (ja) 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ[3,2−d]ピリミジン−4−オン誘導体
JPH09301958A (ja) 1996-05-09 1997-11-25 Nippon Shoji Kk 新規ピリミジン化合物及び抗ロタウイルス剤
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
MXPA03003221A (es) 2000-10-12 2004-12-03 Boehringer Ingelheim Pharma Monohidrato cristalino, procedmiento para su preparacion y su uso para la preparacion de un medicamento.
DE10064994A1 (de) 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
CN100586948C (zh) 2001-06-22 2010-02-03 贝林格尔英格海姆法玛两合公司 结晶性抗胆碱能药,其制备方法及其在药物制备中的用途
US6587548B2 (en) 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
WO2003055890A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2003202263A1 (en) 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
MXPA04012393A (es) 2002-06-12 2005-06-17 Chemocentryx Derivados de piperazina 1-aril-4-substituidos para utilizar como antagonistas ccr1 para tratamiento de inflamacion y desordenes inmunes.
DE602004021585D1 (de) 2003-04-29 2009-07-30 Pfizer Ltd 5,7-DIAMINOPYRAZOLOi4,3-D PYRIMIDINE ZUR VERWENDUNG IN DER BEHANDLUNG VON BLUTHOCHDRUCK
KR101295390B1 (ko) 2003-10-02 2013-09-17 마텍 바이오싸이언스스 코포레이션 변형량의 염소 및 칼륨을 사용하는 미세조류 중에 고농도 디에치에이의 생산
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
SI1874781T1 (sl) 2006-04-19 2009-12-31 Boehringer Ingelheim Int Dihidrotienopirimidini za zdravljenje vnetnih obolenj
WO2008128942A1 (en) 2007-04-20 2008-10-30 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
MX2010003826A (es) 2007-10-18 2010-04-21 Boehringer Ingelheim Int Preparacion de dihidrotieno [3,2-d] pirimidinas e intermedios usados en la misma.
EP2231647A4 (en) 2007-10-19 2011-08-31 Astrazeneca Ab TETRAZONE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS)
WO2009053268A1 (de) 2007-10-19 2009-04-30 Boehringer Ingelheim International Gmbh Neue phenyl-substituierte piperazino-dihydrothienopyrimidine
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
WO2009050242A2 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
MX2010004026A (es) 2007-10-19 2010-04-30 Boehringer Ingelheim Int Piperidino-dihidrotienopirimidinas sustituidas.
AR068888A1 (es) 2007-10-19 2009-12-16 Schering Corp Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp.
WO2009050236A1 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Neue piperazino-dihydrothienopyrimidin-derivate
JP2012519160A (ja) 2009-02-27 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pde4阻害剤及びnsaidを含有する組み合わせ薬
JP2012519159A (ja) 2009-02-27 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pde4阻害剤及びnsaidを含有する複合薬

Also Published As

Publication number Publication date
CN101426505A (zh) 2009-05-06
JP2010523467A (ja) 2010-07-15
MX2008012915A (es) 2008-10-15
US8604039B2 (en) 2013-12-10
CA2647243A1 (en) 2007-10-25
ECSP088738A (es) 2008-10-31
NO20083710L (no) 2008-11-18
US20120108534A1 (en) 2012-05-03
CO6140032A2 (es) 2010-03-19
AU2007239573A1 (en) 2007-10-25
AR060516A1 (es) 2008-06-25
JP5214588B2 (ja) 2013-06-19
EA200802051A1 (ru) 2009-04-28
BRPI0710459A2 (pt) 2011-08-16
US20140005154A1 (en) 2014-01-02
KR20090009885A (ko) 2009-01-23
EP1847543A1 (de) 2007-10-24
IL194739A0 (en) 2009-08-03
EP2010185A1 (de) 2009-01-07
UY30287A1 (es) 2007-11-30
US20080096882A1 (en) 2008-04-24
WO2007118793A1 (de) 2007-10-25
TW200808811A (en) 2008-02-16
US8114878B2 (en) 2012-02-14
EP2010185B1 (de) 2012-06-13
ZA200807015B (en) 2010-01-27
US8822474B2 (en) 2014-09-02

Similar Documents

Publication Publication Date Title
PE20080319A1 (es) Dihidrotienopirimidinas como agentes inhibidores de pde-4
PE20091840A1 (es) Inhibidores de piridilo de la senalizacion hedgehog
PE20141375A1 (es) Activadores de glucoquinasa
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
PE20110136A1 (es) Compuestos organicos
MY142807A (en) Benzimidazole derivative and use thereof.
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
MY177250A (en) Novel nicotinamide derivative or salt thereof
DK2029547T3 (da) FXR-agonister
WO2007026920A3 (en) Amide derivatives as rock inhibitors
NZ607794A (en) N-acylsulfonamide apoptosis promoters
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
MX2009010953A (es) Terapia anticoagulante en combinacion, con un compuesto que actua como un inhibidor del factor xa.
TW200700069A (en) Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
PE20141120A1 (es) Compuestos heterociclicos
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
NO20071658L (no) Alkil-pyridiner som 11-beta-inhibitorer for diabetes
PE20080856A1 (es) Inhibidores de metaloproteasas de matriz
NZ598750A (en) Therapeutic agent for mood disorders
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载